Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

NCT05856513 ·Status: COMPLETED ·Phase: PHASE1

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04166942 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

NCT04293029 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

NCT05684653 ·Status: UNKNOWN ·Phase: PHASE1

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

NCT04305392 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

NCT04772612 ·Status: COMPLETED ·Phase: PHASE1

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT04604496 ·Status: COMPLETED ·Phase: PHASE1

Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir

NCT05731804 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05517525 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

NCT01433458 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

NCT04587622 ·Status: COMPLETED ·Phase: PHASE1

Effect of Hepatic Impairment on LDE225..

NCT01764776 ·Status: COMPLETED ·Phase: PHASE1

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

NCT00781430 ·Status: COMPLETED ·Phase: PHASE1

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

NCT04631549 ·Status: UNKNOWN ·Phase: PHASE1

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

NCT01239459 ·Status: COMPLETED ·Phase: PHASE1

Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury

NCT06547229 ·Status: ACTIVE_NOT_RECRUITING

GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

NCT05814926 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

NCT07282093 ·Status: RECRUITING ·Phase: PHASE1

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

NCT04631575 ·Status: UNKNOWN ·Phase: PHASE1

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

NCT05559242 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

NCT04819464 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

NCT04116476 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

NCT04887064 ·Status: COMPLETED ·Phase: PHASE1

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042 ·Status: COMPLETED ·Phase: PHASE1